Article Text

Hybrid type 1 effectiveness/implementation trial of the international Guide for Monitoring Child Development: protocol for a cluster-randomised controlled trial
  1. Abhishek Raut1,
  2. Revan Mustafayev2,
  3. Roopa Srinivasan3,
  4. Anita Chary4,
  5. Ilgi Ertem5,
  6. Maria del Pilar Grazioso6,
  7. Subodh Gupta1,
  8. Vibha Krishnamurthy3,
  9. Chunling Lu7,8,
  10. Chetna Maliye1,
  11. Ann C Miller9,
  12. Bradley H Wagenaar10,11,
  13. Peter Rohloff4,7
  1. 1Department of Community Medicine, Dr. Sushila Nayar School of Public Health, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Maharashtra, India
  2. 2Department of Pediatrics, Acibadem Maslak Private Hospital, Istanbul, Turkey
  3. 3Ummeed Child Development Center, Mumbai, Maharashtra, India
  4. 4Center for Indigenous Health Research, Wuqu' Kawoq | Maya Health Alliance, Tecpán, Chimaltenango, Guatemala
  5. 5Developmental-Behavioral Pediatrics Division, Department of Pediatrics, Faculty of Medicine, Ankara University, Ankara, Turkey
  6. 6Proyecto Aigle, Guatemala, Guatemala
  7. 7Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA
  8. 8Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA
  9. 9Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA
  10. 10Department of Global Health, University of Washington, Seattle, Washington, USA
  11. 11Department of Epidemiology, University of Washington, Seattle, Washington, USA
  1. Correspondence to Dr Peter Rohloff; prohloff{at}


Introduction More than 40% of children under 5 years of age in low-income and middle-income countries are at risk of not reaching their developmental potential. The international Guide for Monitoring Child Development (GMCD) early intervention package is a comprehensive programme to address developmental difficulties using an individualised intervention plan for young children and their families. We will conduct a hybrid type 1 effectiveness–implementation evaluation of the GMCD intervention in rural India and Guatemala.

Methods and analysis Using a cluster-randomised design, 624 children aged 0–24 months in 52 clusters (26 in India, 26 in Guatemala) will be assigned to usual care or the GMCD intervention plus usual care delivered by frontline workers for 12 months. After 12 months, the usual care arm will cross over to the intervention, which will continue for 12 additional months (24 total). The intervention will be delivered using a digital mobile device interface. Effectiveness will be assessed for developmental functioning (Bayley Scales of Infant Development, 3rd edition) and nurturing care (Home Observation for Measurement of the Environment Scale) outcomes. Implementation will be assessed using the Reach, Effectiveness, Adoption, Implementation, Maintenance framework. Explanatory qualitative analysis guided by the Consolidated Framework for Implementation Research will explore determinants between clusters with high versus low implementation effectiveness.

Ethics and dissemination The study has been approved by the Institutional Review Boards of Brigham and Women’s Hospital, Mahatma Gandhi Institute of Medical Sciences and Maya Health Alliance; and by the Indian Council of Medical Research/Health Ministry Screening Committee. Key study findings will be published in international open-access journals.

Trial registration number NCT04665297, CTRI/2020/12/029748.

Protocol version 1.0 (12 November 2020).

  • data collection
  • health services research
  • psychology

Data availability statement

Data are available in a public, open access repository.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

What is already known on this topic?

  • More than 40% of children under 5 years of age are at risk of not achieving their developmental potential.

  • Caregiver support interventions are an evidence-based approach to support early child development.

  • The Guide for Monitoring Child Development (GMCD) early intervention package is designed for use in low-income and middle-income countries, but real-world effectiveness data are lacking.

What this study hopes to add?

  • Effectiveness data for the GMCD from rural India and Guatemala for child development and nurturing care outcomes.

  • The study includes detailed comparative implementation assessments which will identify important barriers and facilitators to the use of GMCD.


In low/middle-income countries (LMICs), over 40% of children under age 5 are at risk of not reaching their developmental potential.1 2 This inequity has profound implications for children and for LMICs.3 The WHO and UNICEF Nurturing Care Framework calls for health and social systems to support caregivers to optimise children’s development potential.4 Major evidence gaps remain for caregiver support and early child development interventions led by frontline workers.

The international Guide for Monitoring Child Development (GMCD) early intervention package is a comprehensive programme based on bioecological theory for use with children 0–42 months of age. It addresses developmental difficulties using an individualised approach based on functional milestones and family strengths, rather than age-specific recommendations.5–8 GMCD developmental milestones for expressive and receptive language, gross and fine motor, relating, play and self-help have been validated in Argentina, India, South Africa and Turkey.6 8 Two expert panels have rated the GMCD as the highest-performing instrument available for monitoring and developmental support in LMICs.9 10 The package is now available in digital format using the Android operating system.

To date, however, no clinical trials have studied the GMCD’s effectiveness. In this study, we will conduct a hybrid type 1 effectiveness/implementation assessment in India and Guatemala. The study will use a non-blinded, two-arm parallel group cluster-randomised design with a planned cross-in of the control group into the intervention. The primary objectives are (a) to evaluate the effectiveness of the GMCD intervention; (b) to use an implementation science framework to understand barriers and facilitators and (c) to conduct an economic evaluation.

Methods and analysis

Study setting

We will work in rural India and Guatemala where many children under 5 years are at risk for suboptimal development (84% and 70%, respectively).1 In Guatemala, the partner is Maya Health Alliance, a primary care organisation working with rural families of Indigenous Maya ethnicity. Each study cluster in Guatemala will consist of village-based clinical programmes coordinated by a frontline worker from Maya Health Alliance or another collaborating organisation. In India, the partner is Mahatma Gandhi Institute of Medical Sciences (MGIMS), which will work closely with Anganwadi workers in the state of Maharashtra. Anganwadi workers are frontline workers who provide services to children through the government’s Integrated Child Development Services programme. Each cluster in India will consist of two Anganwadi centres and its affiliated workers.

Eligibility criteria

Families of children aged 0–24 months that are eligible to receive services from frontline workers will be eligible. Children who are critically ill and are judged by staff to require center-based care and children whose caregivers do not provide consent will be excluded.


The GMCD early intervention package guides frontline workers through caregiver visits, using seven steps (box 1) that employ family-centred care principles, open-ended interviewing and mutual problem-solving skills. The GMCD intervention is available as a digital Android application, which will be used in this study.

Box 1

Seven steps of the monthly Guide for Monitoring Child Development early intervention visit

  • Explain the importance of the early years for brain development to caregiver.

  • Elicit high-priority caregiver concerns about the child’s development.

  • Assess the child’s functioning in developmental domains using open-ended questions and standardised age-appropriate milestones.

  • Explore existing psychosocial risk factors and nurturing care already provided by the family, elicit and support child and family strengths.

  • Provide specific recommendations for nurturing care activities for the child’s level of functioning in seven domains of development.

  • Problem solve other opportunities to address child health and psychosocial risk factors.

  • Set mutual goals around interventions, referrals to community resources and plans for the next visit.

In this trial, the GMCD intervention will be integrated into existing usual care monthly home visits delivered by frontline workers. Details of usual care will differ from cluster to cluster, but typically include health promotion activities such as growth monitoring and immunisations, and nutritional support activities such as complementary feeding education and supplementation. Individuals not enrolled in the intervention will receive all usual care activities.

Frontline workers will be trained in use of the GMCD intervention through group sessions and individual practice by certified trainers. Training will consist of 30–40 contact hours with additional time between training sessions to allow for practice of new skills. Final competence will be assessed by direct observation by GMCD trainers.


Based on our preliminary work, we expect to observe improvements across all developmental domains but expect the largest changes to be in language.11 Therefore, we will use change from 0 to 12 months in the language composite score of the Bayley Scales of Infant Development, 3rd edition (BSID-3) as our primary developmental outcome.12 Our secondary outcome is improvement in nurturing care. To assess this, we will measure changes from 0 to 12 months in the Home Observation for Measurement of the Environment Scale (HOME).13

Participant timeline

Participants will be assigned to usual care or the GMCD intervention for 12 months. After 12 months, the usual care arm will cross-in to the intervention, which will continue in both arms for 24 total months. A schematic of participant enrollment, study visits and assessments is given in figure 1, and key instruments are summarised in table 1. Representative data collection forms in English are given in online supplemental file 1.

Supplemental material

Figure 1

Schematic of study timeline and participant flow. BSID3, Bayley Scales of Infant Development, 3rd edition; GMCD, Guide for Monitoring Child Development; HOME, Home Observation for Measurement of the Environment Scale.

Table 1

Details of study data collection instruments

Sample size and recruitment

Our total sample size is 624 children in 52 clusters, n=312 (26 clusters) in India and n=312 (26 clusters) in Guatemala. Our primary effectiveness outcome is to compare the difference in mean BSID3 Scores at 12 months. Cohen’s d effect sizes of recent community-based integrated parenting interventions on children’s development including studies in India and Guatemala have ranged from 0.3 to 0.4 SDs.11 14–17 Assuming an intracluster correlation coefficient of 0.2 and refusals and attrition of 25%, our sample size will have 80% power to detect an overall difference of 0.3 SD on the BSID3 language composite score. The sample size is also powered to allow independent analysis of each site at a difference of 0.4 SD with 80% power.

Research staff will obtain lists of eligible children from participating frontline workers. Study nurses will join the frontline health worker at enrollment home visits, confirm eligibility and solicit informed consent. These recruitment activities will be supplemented with phone calls or additional home visits as needed.

Allocation and blinding

At study initiation, 52 clusters (26 each in India and Guatemala) will be randomly allocated in a 1:1 ratio to the study arms with stratification by country. Unique identifier number for clusters will be provided to the Boston-based study statistician in lieu of names prior to randomisation, which will be constrained to provide balance on covariates of chronic child malnutrition and distance to nearest health centre.18 The statistician will generate the randomisation scheme using Stata’s CVCRAND command (College Station, Texas, USA) which uses computerised randomisation sequence generation to generate and select a scheme meeting pre-determined constraint requirements.

Once the clusters have been assigned, eligible children will be randomly ordered on the list and the first six children whose caregivers consent will be enrolled for each of two age categories (0–12 months and 13–24 months, n=12 per cluster). Only one child per family will be enrolled. All study participants in the same cluster will be assigned to the same study arm. All age eligible children within a frontline worker’s coverage area will receive the intervention as caregivers wish, but data on endpoints will only be collected on study-enrolled children. Assessors conducting development tests and the study statistician will remain blinded.

Data collection and management

An outline of instruments is given in table 1. Most data will be entered online into a REDCap database (hosted by each country lead institution or Brigham and Women’s Hospital).19 Data entry and quality control checks on at least 10% of data will be conducted weekly by study coordinators. Study staff will collect all planned data points for agreeable participants who drop out of the intervention. The study will include haemoglobin analysis using the Hemocue Hb 201 device ( which will be acquired locally by each of the participating field sites.

Primary statistical analysis

Our main intention-to-treat analysis will assess the mean differences between arms using t-tests or Wilcoxon-Mann-Whitney tests (as appropriate) and regression modelling of BSID scaled composite scores using the following mixed-effects model:

Embedded Image

where Yij is the BSID composite scaled score of participant j in cluster i; δ=treatment effect of interest (difference between group mean BSID Scores); X=cluster assignment, and u and e are random intercepts at cluster and participant levels, respectively. Results will be reported as the difference in scores between groups. We will conduct sensitivity analyses controlling for any remaining baseline imbalances at participant or cluster level. Because mixed effects models are robust to data missing at random (MAR), we will assess data missingness.20 If missing data is not MAR, we will conduct multilevel multiple imputation.

Implementation and qualitative analyses

We will use the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework to assess implementation outcomes as outlined in figure 2.21 We will also conduct explanatory qualitative analyses to determine the factors that distinguish high-performing and low-performing clusters in both sites. These analyses will be guided by Consolidated Framework for Implementation Research (CFIR) constructs, principally from the Intervention Characteristics and Inner Settings domains which are especially relevant for our early-stage hybrid type 1 trial design (table 2).22 23

Figure 2

Description of RE-AIM dimensions and related indicators to be assessed. BSID3, Bayley Scales of Infant Development, 3rd edition; HOME, Home Observation for Measurement of the Environment Scale; RE-AIM, Reach, Effectiveness, Adoption, Implementation, Maintenance framework.

Table 2

Consolidated Framework for Implementation Research constructs planned for use in comparative site analysis

To conduct these analyses, 6–8 clusters in each site will be identified based on differences on RE-AIM measures. Subsequently, we will conduct in-depth interviews and focus group discussions with implementing providers. An interview codebook will be constructed following CFIR constructs and transcripts will be double coded. After this, two coders will rate the CFIR constructs to reflect their positive or negative influence and the strength of each for distinguishing high and low performance.24

Economic evaluation

We will perform a costing exercise and cost-effectiveness analysis as previously described.25–29 System-level cost assessments will be structured around the WHO framework for health systems.30 Costs incurred by frontline personnel will include time or money spent in training and evaluation sessions. Costs incurred by caregivers and families will include time spent on GMCD visits.

Incremental costs of the interventions compared with control will be generated using multilevel regression analysis with generalised linear models (for skewed cost data and clustering effects).31–34 To provide mean and 95% CIs for incremental costs, we will use non-parametric methods based on bootstrapped estimates of mean costs.35 36 A discount rate of 3% will be applied to costs, adjusted between 0% and 6% for sensitivity tests. The same strategy will be used to obtain incremental effectiveness and cost-effectiveness ratios.

Ethics and dissemination

Data monitoring and safety

As an unblinded trial of minimal risk, the principal study investigators will review study progress and safety. Oversight by an independent Data Safety Monitoring Board is not planned. No stopping rules are planned. Principal investigators or key delegates will audit trial data, including subject accrual and status, compliance with study procedures, complaints and protocol deviations on at least a monthly basis with reports to overseeing ethics committees.

Patient and public involvement

Patients and the public were not involved in the development of the protocol. Investigators will hold dissemination meetings with community leaders in each site to discuss interim lessons learnt and final outcomes.

Ethics approvals, risks, benefits

The study has been approved by the Institutional Review Boards of Brigham and Women’s Hospital (2020P002143), MGIMS (IEC/COMMED/105/2020) and Maya Health Alliance (WK 2020 003); and by the Indian Council of Medical Research/Health Ministry Screening Committee (2020-10139). Any protocol changes will be approved by the above committees.

This project involves a minimal risk intervention, and adverse intervention-related outcomes are not anticipated. During the capillary blood sample collection for haemoglobin assessment, there is risk of temporary discomfort to the child and rare risk of infection. For caregiver participants, risks include lost productivity because of time requirements and psychological distress from discussing any potential or observed developmental delays in their children. An individual experiencing adverse health outcomes while participating in the study will be referred to clinical care by the study team. Compensation or defrayment of medical costs will not be provided. Children and caregivers in the clinical trial in both control and intervention arms will benefit from access to a panel of developmental tests which they otherwise may not have access to. The intervention arm (and the control arm after 12 months) will receive intensive individualised support to promote early child development.

Informed consent and confidentiality

Consent will be at the individual caregiver level, not the cluster level. In Guatemala, study staff members will use a verbal informed consent script. There is emerging international consensus that verbal informed consent is appropriate in contexts where signed informed consent may not be culturally appropriate.37 In Guatemala, the primary ethics committee encourages verbal informed consent given the legacy of historical trauma and discrimination against indigenous populations and low levels of literacy.38 During the Guatemalan civil war, individuals who were not literate could be made to sign documents as an oppressive strategy for extracting resources and confessions.39 This study will not replicate those potentially traumatic practices. All consent procedures will occur in the language of the participant’s choosing. Research staff in Guatemala will be natively fluent in local Mayan languages and Spanish. Study staff member will record the date of verbal consent and provide a copy of the script to the caregiver.

In India, study staff members will read the informed consent, or the caregiver will be given time to read the document, according to preference. All consent procedures will occur in the language of the participant’s choosing. Research staff in India will be natively fluent in Marathi and Hindi. After reading the document, if the caregiver agrees to participate, they will sign the consent document and receive a copy.

To protect confidentiality, all paper research forms will be kept in locked file cabinets. Most data from study visits will be entered directly online, with entries linked only to subject identifying numbers. Once data extraction and cleaning has been completed, the analysis phase will be de-identified.

Dissemination policy

All research results will be made available in the public domain. The principal investigator and the co-investigators will ensure that these are disseminated through presentations at national (India, Guatemala) and international conferences. Authorship on publication will follow ICMJE guidelines.

We will share variable dictionaries, definitions and de-identified data from clinical trial participants. The lack of sensitive data elements in the dataset, the remote locations and de-identification procedures make deduction of study participants unlikely. We will deposit the data in a suitable public data repository, and it will be freely available there for any researcher who adheres to the procedures of the repository. We will submit datasets no later than 2 years after the publication of the main study paper.

Data availability statement

Data are available in a public, open access repository.

Ethics statements

Patient consent for publication

Ethics approval

Brigham and Women's Hospital (2020P002143), Mahatma Gandhi Institute of Medical Sciences (IEC/COMMED/105/2020), Maya Health Alliance (WK 2020 003), Indian Council of Medical Research/Health Ministry Screening Committee (2020-10139).


Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.


  • Contributors AC, IE, MdPG, SG, VK, CL, ACM, BHW, PR contributed to conceptualisation. PR contributed to funding acquisition. AR, RM, RS, AC, SG, CL, CM, ACM, BHW, PR contributed to methodology. AR, RS, MdPG, SG, CM, PR contributed to supervision. AR, PR contributed to writing, original draft. AR, RM, RS, AC, IE, MdPG, SG, VK, CL, CM, ACM, BHW contributed to writing, review and editing.

  • Funding USA National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development, 1R01HD100984-01A1.

  • Disclaimer The study sponsor will not be involved in study design; collection, management, analysis, and interpretation of data; writing of reports; or the decision to submit reports for publication.

  • Competing interests No, there are no competing interests.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.